EDWARDS LIFESCIENCES CORP

Insider trade: Edwards Lifesciences CVP Lippis Daniel buys 619 shares at $72.68, sells at $85.65, signaling confidence in its TAVR business and future upside.

Insider sale by Edwards Lifesciences SVP Andrew Dahl: 253 shares at $84.37 amid rising social‑media buzz, yet fundamentals remain solid—watch for market impact.

Bruls’ recent 2,644‑share sale at $89.98 reflects a careful, profit‑taking strategy amid Edwards Lifesciences’ rally—what it signals for insiders and investors.

Markowitz Wayne’s July 30, 2026 sale at Edwards Lifesciences signals short‑term liquidity play amid rising social‑media buzz and high valuation multiples.

Bruls Annette’s modest 109‑share sale at Edwards Lifesciences signals routine liquidity needs, not a warning—insider buying stays strong and the company’s growth outlook remains solid.

Edwards Lifesciences insiders buying RSUs and options signal confidence in its growth, boosting investor confidence in high‑growth heart‑valve tech.

Insider sale of 567 shares by Edwards Lifesciences SVP Andrew M. Dahl – what this signals for investor confidence and future stock performance.

Edwards Lifesciences insider trading: Bobo’s rapid buy‑sell patterns reveal a cautious yet bullish stance—watch for short‑term volatility around earnings and product launches.

CEO Bernard Zovighian’s recent 47,207‑share purchase in Edwards Lifesciences signals modest insider confidence amid a near‑52‑week low, highlighting routine trading and solid fundamentals for long‑term value.

Insider trades show CFO Ullem Scott’s confidence in Edwards Lifesciences—buy‑sell cycle highlights strategic confidence and a strong future outlook.